New combo therapy aims to boost survival in kids with aggressive blood cancer
NCT ID NCT02405676
First seen Mar 29, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This study tests whether adding 4 injections of rituximab to stronger chemotherapy can help children and teens with mature B-cell non-Hodgkin lymphoma or B-cell acute leukemia live longer without the cancer coming back. About 200 participants in China will receive the new regimen, and their outcomes will be compared to a previous study. The goal is to improve event-free survival, especially for those with advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Second University Hospital of Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.